指南与共识神经MRPET

苏格兰学院间指南网络痴呆指南:疑似痴呆的检查(SIGN 168)聚焦生物标志物的执行摘要

Scottish Intercollegiate Guidelines Network Guidance on Dementia: The Investigation of Suspected Dementia (SIGN 168) with Focus on Biomarkers-Executive Summary.
指南 / 共识 · Thromb Haemost · 2024-05-24

本文为苏格兰学院间指南网络(SIGN)痴呆指南组关于疑似痴呆检查的执行摘要,属于2023年11月发布的SIGN 168指南的子部分。指南组聚焦影像与液体生物标志物诊断痴呆的最新证据,证据审查支持考虑使用结构影像、核医学影像及已确立的阿尔茨海默病脑脊液生物标志物(淀粉样蛋白与tau)辅助诊断;不推荐常规使用淀粉样蛋白PET,但将专科指导下用于不典型或青年起病的疑似阿尔茨海默病痴呆患者作为临床良好实践要点。

要点

  • 证据审查支持考虑结构影像、核医学影像及脑脊液淀粉样蛋白与tau生物标志物用于痴呆诊断。
  • 不推荐常规使用淀粉样蛋白PET影像。
  • 淀粉样蛋白PET可在专科指导下用于不典型或青年起病的疑似阿尔茨海默病痴呆患者(临床良好实践要点)。

核心结论

  • 证据审查支持考虑使用结构影像、核医学影像及已确立的阿尔茨海默病脑脊液生物标志物(淀粉样蛋白与tau)诊断痴呆;不推荐常规使用淀粉样蛋白PET,但专科指导下用于不典型或青年起病的疑似阿尔茨海默病痴呆患者被列为临床良好实践要点。

研究设计与样本

  • 苏格兰学院间指南网络(SIGN)痴呆指南组制定的指南执行摘要,属于2023年11月发布的SIGN 168指南的子部分;指南组包括老年精神病学、神经病学、放射学与核医学专家,并有SIGN与苏格兰医疗改进团队同事支持,照护者与支持组织代表参与以确保推荐适合受评估者及其照护者视角;因2018年NICE痴呆审查已包含痴呆检查证据审查,SIGN指南制定组决定聚焦影像与液体生物标志物诊断痴呆的最新证据审查。

诊断标准与关键数值

  • 证据审查支持考虑使用结构影像诊断痴呆。
  • 证据审查支持考虑使用核医学影像诊断痴呆。
  • 证据审查支持考虑使用已确立的阿尔茨海默病脑脊液生物标志物(淀粉样蛋白与tau)诊断痴呆。
  • 不推荐常规使用淀粉样蛋白PET影像。
  • 淀粉样蛋白PET在专科指导下用于不典型或青年起病的疑似阿尔茨海默病痴呆患者被列为临床良好实践要点。

临床应用与阅片要点

  • 指南与摘要纳入NICE关于标准检查及更专业检查的指导,为考虑更先进诊断生物标志物检查提供背景。
  • 不推荐常规使用淀粉样蛋白PET影像。
  • 淀粉样蛋白PET可在专科指导下用于不典型或青年起病的疑似阿尔茨海默病痴呆患者(临床良好实践要点)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

This is an executive summary of the recent guidance produced by the Scottish Intercollegiate Guidelines Network (SIGN) dementia guideline group with regards to the investigation of suspected dementia. This is a sub-section of the broader SIGN 168 guideline released in November 2023. The guideline group included clinicians with expertise in Old Age Psychiatry, Neurology, Radiology, and Nuclear Medicine supported by colleagues from the SIGN and Healthcare Improvement Scotland teams. There was representation from carers and support organizations with experience of dementia, to ensure the recommendations were appropriate from the perspective of the people being assessed for possible dementia and their carers. As the 2018 National Institute for Health and Clinical Excellence (NICE) dementia review included a review of the evidenced investigation of dementia, the SIGN guideline development group decided to focus on a review on the up-to-date evidence regarding the role of imaging and fluid biomarkers in the diagnosis of dementia. To give context to the consideration of more advanced diagnostic biomarker investigations, the guideline and this summary include the NICE guidance on the use of standard investigations as well as more specialist investigations. The evidence review supports consideration of the use of structural imaging, nuclear medicine imaging, and established Alzheimer's cerebrospinal fluid biomarkers (amyloid and tau) in the diagnosis of dementia. Although routine use of amyloid positron emission tomography imaging was not recommended, its potential use, under specialist direction, in patients with atypical or young-onset presentations of suspected Alzheimer's dementia was included as a clinical good practice point.

来源:Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mackay GA, Gall C, Jampana R, et al. Scottish Intercollegiate Guidelines Network Guidance on Dementia: The Investigation of Suspected Dementia (SIGN 168) with Focus on Biomarkers-Executive Summary. Thromb Haemost. 2024. PMID: 38788775. doi:10.1055/a-2332-6426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。